Tricida, Inc.
7000 Shoreline Court, Suite 201
South San Francisco
California
94080
United States
111 articles about Tricida, Inc.
-
Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis
3/28/2019
Blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E, met its primary and all secondary endpoints, supporting the long-term safety and efficacy profile of TRC101
-
Tricida Announces $200 Million Debt Facility With Hercules Capital
3/28/2019
Tricida, Inc. announced that it has entered into an amendment to its existing debt facility with Hercules Capital, Inc., a leader in customizing debt financing for companies in the life sciences and technology-related markets.
-
Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results
3/28/2019
Tricida, Inc. announced financial results for the three months and full year ended December 31, 2018 and provided an update on key initiatives.
-
Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019
3/27/2019
Tricida, Inc. announced that it will report results from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning at 7:15 am Eastern Time.
-
Tricida to Report Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 28, 2019
3/7/2019
Tricida, Inc. announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019.
-
Tricida to Present at the Cowen and Company 39th Annual Health Care Conference
2/27/2019
Geoff Parker, Tricida’s Chief Financial Officer, will provide a company overview, business update and progress on the company’s key initiatives.
-
Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer
1/17/2019
Dr. Cantrell will lead Tricida’s commercial planning and operations functions.
-
Tricida to Present at the 37th Annual J. P. Morgan Healthcare Conference
1/2/2019
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 37th Annual J. P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:30 am PT / 2:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s chief executive officer and president, will provide a company overview, business update and progress on the company’s key initiatives.
-
Tricida Announces Third Quarter 2018 Financial Results
11/8/2018
Advanced Key Initiatives for NDA Submission
-
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
-
Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 8, 2018
11/1/2018
Tricida, Inc. announced that it will report its third quarter 2018 financial results after the close of market on Thursday, November 8, 2018.
-
Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28
10/4/2018
Oct. 4, 2018 20:26 UTC Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with
-
Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives
8/8/2018
Completed Positive Pivotal Phase 3 Trial for TRC101
-
Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical Development
8/1/2018
Dr. Parsell will lead Tricida’s clinical development of TRC101
-
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7/2/2018
Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with...
-
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
-
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
-
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
6/5/2018
Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with metabolic acidosis.
-
Tricida Announces Kathryn Falberg Joins Board of Directors
6/4/2018
Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and finance expertise.
-
Tricida Announces $100 Million Venture Debt Financing From Hercules Capital
3/2/2018
Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets.